A Phase 3 interventional study of Casimersen and Golodirsen in Duchenne Muscular Dystrophy, sponsored by Sarepta Therapeutics, Inc.. Terminated at 50 sites in 13 countries. Open to male participants aged 7 Years to 23 Years. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by Sarepta Therapeutics, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc. — 5 open to participants now, 6 under way, 2 of them phase 3. Muscular Dystrophy, Duchenne · Sarepta Therapeutics, Inc..
Among the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., this one is the 3rd largest by enrollment of the 25 interventional ones that give a count, is one of 5 that started in 2018, is one of 7 in phase 3, and was the 13th registered.
482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.
Browse Muscular Dystrophy, Duchenne studies →5 of the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc. are open now, in 9 countries. Recruiting first, the newest first:
Sarepta Therapeutics, Inc. · Sites in United States
Ages 4+ · Men only
Sarepta Therapeutics, Inc. · Sites in United States
Ages 2+ · Men only
Sarepta Therapeutics, Inc. · Sites in United States
Ages 4+ · Men only
Sarepta Therapeutics, Inc. · Sites in United States, Belgium, Germany and 6 more countries
Men only
Sarepta Therapeutics, Inc. · Sites in United States
Men only
By country, each count listing its studies:
Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.
This study: 7 Years to 23 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 12 · Phase 3 7 · Phase 4 1
First in 2009; this study’s year is marked. 5 started in 2018.
This study's enrollment of 171 is above the median of 25 across 333 interventional studies indexed under Muscular Dystrophy, Duchenne.
Median enrollment 24 across the 25 interventional studies, 400 across the 2 observational. Of the 21 that completed or were terminated, 15 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sarepta Therapeutics, Inc. is the lead sponsor of 52 studies on the registry; 8 are open to participants now.
Of its 21 completed or terminated interventional studies of FDA-regulated products, 12 (57%) have results posted.
2 of the studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05881408Phase 3Sarepta Therapeutics, Inc.A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) | 2027-05-31 |
| NCT07542314Sarepta Therapeutics, Inc.Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting | 2027-08-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main objective of this study is to evaluate the safety and tolerability of long-term treatment with casimersen or golodirsen in patients with Duchenne muscular dystrophy (DMD).
Inclusion Criteria:
Other inclusion/exclusion criteria apply.
Patients amenable to exon 45 skipping who have completed a clinical trial evaluating casimersen will receive open-label casimersen intravenous (IV) infusions, weekly, at 30 mg/kg for up to 144 Weeks.
Drug: Casimersen
Patients amenable to exon 53 skipping who have completed a clinical trial evaluating golodirsen will receive open-label golodirsen intravenous (IV) infusions, weekly, at 30 mg/kg for up to 144 Weeks.
Drug: Golodirsen
Casimersen solution for IV infusion
Also known as: SRP-4045, AMONDYS 45
Golodirsen solution for IV infusion
Also known as: SRP-4053, VYONDYS 53
Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)
A treatment-emergent adverse event (TEAE) was any untoward medical occurrence in a clinical study participant that did not necessarily have a causal relationship with the study drug. A TEAE could, therefore, be any unfavorable and unintended symptom, sign, disease, condition, or test abnormality that occurred during or after administration of the study drug, whether or not considered related to the study drug. A TESAE was any TEAE that resulted in any of the following outcomes: death, a life-threatening event, required or prolonged inpatient hospitalization, persistent or significant disability/incapacity, or an important medical event (that is, may have jeopardized the participant and may have required medical or surgical intervention to prevent one of the previously mentioned outcomes). A summary of serious and all other non-serious TEAEs regardless of causality is located in the Reported Adverse Events module.
Time frame: Up to 33 days after the last infusion of study drug (up to approximately 149 weeks)
Participants amenable to exon 53 or exon 45 skipping were enrolled into this study from Study 4045-101 (NCT02530905), Study 4053-101 (NCT02310906), and Study 4045-301 (NCT02500381).
| Milestone | Golodirsen | Casimersen |
|---|---|---|
| Started | 74 | 97 |
| Received at least 1 dose of study drug | 74 | 97 |
| Completed | 26 | 27 |
| Not completed | 48 | 70 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Study terminated by sponsor | 41 | 65 |
| Withdrew: Withdrawal by subject | 6 | 5 |
A treatment-emergent adverse event (TEAE) was any untoward medical occurrence in a clinical study participant that did not necessarily have a causal relationship with the study drug. A TEAE could, therefore, be any unfavorable and unintended symptom, sign, disease, condition, or test abnormality that occurred during or after administration of the study drug, whether or not considered related to the study drug. A TESAE was any TEAE that resulted in any of the following outcomes: death, a life-threatening event, required or prolonged inpatient hospitalization, persistent or significant disability/incapacity, or an important medical event (that is, may have jeopardized the participant and may have required medical or surgical intervention to prevent one of the previously mentioned outcomes). A summary of serious and all other non-serious TEAEs regardless of causality is located in the Reported Adverse Events module.
| Participants | Golodirsen | Casimersen |
|---|---|---|
| Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs) | 12 | 22 |
Collected over Up to 33 days after the last infusion of study drug (up to approximately 149 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Golodirsen | 1/74 (1.4%) | 12/74 (16.2%) | 63/74 (85.1%) |
| Casimersen | 0/97 (0%) | 22/97 (22.7%) | 93/97 (95.9%) |
| Event | Golodirsen | Casimersen |
|---|---|---|
| Femur fractureInjury, poisoning and procedural complications | 3/74 | 8/97 |
| OsteoporosisMusculoskeletal and connective tissue disorders | 1/74 | 2/97 |
| Traumatic fractureInjury, poisoning and procedural complications | 1/74 | 0/97 |
| CellulitisInfections and infestations | 1/74 | 0/97 |
| GastroenteritisInfections and infestations | 1/74 | 0/97 |
| Gastroenteritis viralInfections and infestations | 1/74 | 0/97 |
| HaematuriaRenal and urinary disorders | 1/74 | 0/97 |
| NephrolithiasisRenal and urinary disorders | 1/74 | 0/97 |
| Renal embolismRenal and urinary disorders | 1/74 | 0/97 |
| ScoliosisMusculoskeletal and connective tissue disorders | 1/74 | 1/97 |
| Event | Golodirsen | Casimersen |
|---|---|---|
| NasopharyngitisInfections and infestations | 26/74 | 21/97 |
| VomitingGastrointestinal disorders | 22/74 | 15/97 |
| HeadacheNervous system disorders | 22/74 | 25/97 |
| COVID-19Infections and infestations | 10/74 | 27/97 |
| FallInjury, poisoning and procedural complications | 19/74 | 17/97 |
| Back painMusculoskeletal and connective tissue disorders | 17/74 | 17/97 |
| PyrexiaGeneral disorders | 13/74 | 22/97 |
| CoughRespiratory, thoracic and mediastinal disorders | 12/74 | 19/97 |
| DiarrhoeaGastrointestinal disorders | 13/74 | 11/97 |
| Upper respiratory tract infectionInfections and infestations | 7/74 | 15/97 |
Safety Analysis Set: All enrolled participants who received at least 1 dose of study drug (golodirsen or casimersen).
| Age, Continuous(years) | Golodirsen | Casimersen | Total |
|---|---|---|---|
| Mean | 11.7 ± 2.14 | 12.2 ± 2.57 | 12.0 ± 2.40 |
| Sex: Female, Male(Participants) | Golodirsen | Casimersen | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 74 | 97 | 171 |
| Ethnicity (NIH/OMB)(Participants) | Golodirsen | Casimersen | Total |
|---|---|---|---|
| Hispanic or Latino | 10 | 6 | 16 |
| Not Hispanic or Latino | 54 | 89 | 143 |
| Unknown or Not Reported | 10 | 2 | 12 |
| Race/Ethnicity, Customized(participants) | Golodirsen | Casimersen | Total |
|---|---|---|---|
| White | 65 | 86 | 151 |
| Black | 1 | 0 | 1 |
| Asian | 4 | 7 | 11 |
| American Indian or Alaska Native | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Other | 3 | 3 | 6 |
Ran from Aug 2018 to primary completion in Jul 2023, 59 months.
Results were first posted in Sep 2024, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Casimersen · Golodirsen
Muscular Dystrophy, Duchenne →